close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Akero Therapeutics Inc.

News headline image
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Lancet Publication of the Phase 2b HARMONY Clinical Trial Demonstrating 96 Weeks Treatment with EFX Reduced Liver Fibrosis in Patients with Pre-cirrhotic MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the Jefferies Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Proposed Public Offering of Common Stock
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
From Akero Therapeutics Inc.
Via GlobeNewswire
Tickers AKRO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today